Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Featured ArticleNeurobiology of Disease

Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice

Kavon Rezai-Zadeh, Doug Shytle, Nan Sun, Takashi Mori, Huayan Hou, Deborah Jeanniton, Jared Ehrhart, Kirk Townsend, Jin Zeng, David Morgan, John Hardy, Terrence Town and Jun Tan
Journal of Neuroscience 21 September 2005, 25 (38) 8807-8814; DOI: https://doi.org/10.1523/JNEUROSCI.1521-05.2005
Kavon Rezai-Zadeh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doug Shytle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Mori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huayan Hou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Jeanniton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared Ehrhart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirk Townsend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Zeng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Morgan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Hardy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terrence Town
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Tan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  •   Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    EGCG treatment inhibits Aβ generation in cultured neuronal cells. Aβ1–40,42 peptides were analyzed in conditioned media from SweAPP N2a cells (a, c, d) or TgAPPsw mouse-derived primary neurons (b) by ELISA (n = 3 for each condition). Data are represented as a percentage of Aβ1–40,42 peptides secreted 12 h after EGCG treatment relative to control (untreated). a, b, One-way ANOVA followed by post hoc comparison revealed significant differences between EGCG and the other compounds at 40, 20, 10, and 5 μm treatment concentrations (p < 0.001). c, When comparing EGCG (20 μm) treatment with cotreatment of SweAPP N2a cells with EGCG (20 μm) plus GC (80 μm), C (80 μm), or GC/C, a significant difference was noted for each comparison (p < 0.001). d, SweAPP N2a cells were treated with EGCG at a comparable concentration with that found in GT (GT contains 30% EGCG), and a significant difference was noted between GT and EGCG treatments (40 μg/ml vs 20 μm; 20 μg/ml vs 10 μm; 10 μg/ml vs 5 μm) on inhibition of Aβ generation (p < 0.001 for each comparison). Reduction for each treatment condition is indicated for c and d.

  •   Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    EGCG treatment alters APP cleavage in vitro. a, b, SweAPP N2 a cells were treated with EGCG at 20 μm or PBS (control) for 12 h. Cell lysates were prepared and subjected to Western blot (WB) analysis of APP CTFs (a), and conditioned media were collected for immunoprecipitation (IP)/WB (b). c, d, Cell lysates were prepared from SweAPP N2a cells treated with EGCG at 20μm for a range of time points (c) or EGCG at various doses for 12 h (d) and subjected to WB for APP CTFs. e, g, Cell lysates were prepared from SweAPP N2a cells treated with EGCG (-) EC, (+) EC, GC, C, or GT at the doses indicated for 12 h. For f, SweAPP N2a cells were cotreated with EGCG (20 μm) and GC, C, or GC/C at 80 μm for 12 h. For a and c–g, WB analysis using antibody 369 against the cytoplasmic tail of APP shows full-length holo APP and two bands corresponding to β-CTF (C99) and α-CTF (C83). For b, WB analysis using antibody 22C11 against the N terminus of APP shows sAPP-α (IP with antibody 6E10 directed against Aβ1–17) and sAPP-β [following immunodepletion (ID) with 6E10 and subsequent IP with 22C11]. a, c, d, g, Western blot analysis with anti-actin antibody shows actin protein (as an internal reference control). Densitometry analysis shows the ratio of α-CTF to β-CTF as indicated below the figures. a, A t test revealed a significant difference between EGCG treatment and control (n = 3 for each condition; p < 0.001). f, One-way ANOVA showed significant between-groups differences (p < 0.01) with n = 4 for each condition, and post hoc comparison revealed a significant difference between EGCG and EGCG/GC/C treatments (p < 0.001). Similar results were observed in N2a cells transfected with human wild-type APP695 using 369 antibody and in SweAPP N2a cells using Calbiochem polyclonal APP C-terminal APP antibody (data not shown).

  •   Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    EGCG treatment promotes α-secretase cleavage of APP in vitro. a, b, Cell lysates were prepared from SweAPP N2a cells treated with EGCG (20μm) for different time points as indicated. a, Western blot analysis by anti-TACE antibody shows TACE and cleaved fragments. b, α-, β-, and γ-secretase cleavage activities were analyzed in cell lysates using secretase cleavage activity assays. Data are presented as a percentage of fluorescence units/milligrams protein activated 1, 2, or 3 h after EGCG treatment relative to control (PBS). A t test revealed a significant difference betweenα-secretase and either β- or γ-secretase cleavage activity at 1, 2, and 3 h after EGCG treatment (p < 0.001). c–e, SweAPP N2a cells were treated with EGCG (20 μm) or PBS (control) in the presence or absence of TAPI-1 at various doses (c) or at 25 μm (d, e) for 4 h. Cell-cultured supernatants were collected, and cell lysates were prepared from cultured cells. c, Western blot analysis by antibody 369 shows holo APP and two bands corresponding to β-CTF and α-CTF. d, Data are represented as percentage of α-secretase cleavage activity calculated in terms of fluorescence units/milligrams protein after EGCG treatment relative to control (PBS) 4 h after EGCG treatment in the presence or absence of TAPI-1. A t test revealed a significant difference between EGCG treatment and cotreatment with EGCG and TAPI-1 (p < 0.001); increased levels of activity are indicated. e, Data are presented as percentage of Aβ secretion relative to PBS control 4 h after EGCG treatment in the presence or absence of TAPI-1. A t test revealed a significant difference between EGCG and EGCG plus TAPI-1 treatment (p < 0.001); reduction for each treatment condition is indicated.

  •   Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    EGCG promotes nonamyloidogenic APP processing and reduces cerebral amyloidosis in TgAPPsw mice. Brain homogenates were prepared from female TgAPPsw mice treated with EGCG (n = 11) or PBS (n = 9). a, Top, Western blot analysis by antibody 369 shows holo APP and two bands corresponding to β-CTF and α-CTF. a, Middle and bottom, Western blot analysis by antibody 22C11 shows holo APP (middle; following ID/C-terminal APP antibody) and sAPP-α (bottom; following ID/C-terminal APP antibody and IP/6E10). Detergent-soluble Aβ1–40,42 (b) and insoluble Aβ1–40,42 prepared with 5 m guanidine (c) were analyzed by ELISA. Data are presented as mean ± 1 SEM of Aβ1–40 or Aβ1–42 (pg/mg protein) separately. For b and c, a t test revealed a significant between-groups difference for either soluble or insoluble Aβ1–40,42 (p < 0.001 for each comparison). d, α-, β-, and γ-secretase cleavage activities were analyzed by secretase cleavage activity assays. Data are presented as mean ± 1 SEM of fluorescence units/mg protein. A t test revealed a significant difference between EGCG- and PBS-treated Tg APPsw mice for α-secretase activity (p < 0.001). e, Mouse brain coronal paraffin sections were stained with anti-human Aβ antibody (4G8). Left, Control PBS-treated mice. Right, EGCG-treated mice. The top panels are from the cingulate cortex (CC), the middle panels are from the hippocampus (H), and the bottom panels are from the entorhinal cortex (EC). f, Percentages of 4G8-immunoreactive Aβ plaques (mean ± 1 SEM) were calculated by quantitative image analysis, and reduction for each brain region is indicated. g, Mouse brain sections from the indicated brain regions were stained with thioflavin S. Left, Control PBS-treated mice. Right, EGCG-treated mice. h, Percentage of thioflavin S plaques (mean ± 1 SEM) were quantified by image analysis, and reduction for each brain region is indicated. A t test for independent samples revealed significant differences (p < 0.005) between groups for each brain region examined in f and h. Scale bar, 50 μm.

Back to top

In this issue

The Journal of Neuroscience: 25 (38)
Journal of Neuroscience
Vol. 25, Issue 38
21 Sep 2005
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice
Kavon Rezai-Zadeh, Doug Shytle, Nan Sun, Takashi Mori, Huayan Hou, Deborah Jeanniton, Jared Ehrhart, Kirk Townsend, Jin Zeng, David Morgan, John Hardy, Terrence Town, Jun Tan
Journal of Neuroscience 21 September 2005, 25 (38) 8807-8814; DOI: 10.1523/JNEUROSCI.1521-05.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice
Kavon Rezai-Zadeh, Doug Shytle, Nan Sun, Takashi Mori, Huayan Hou, Deborah Jeanniton, Jared Ehrhart, Kirk Townsend, Jin Zeng, David Morgan, John Hardy, Terrence Town, Jun Tan
Journal of Neuroscience 21 September 2005, 25 (38) 8807-8814; DOI: 10.1523/JNEUROSCI.1521-05.2005
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

  • Axonal ER Ca2+ Release Selectively Enhances Activity-Independent Glutamate Release in a Huntington Disease Model
  • Involvement of GABAergic Interneuron Subtypes in 4-Aminopyridine-Induced Seizure-Like Events in Mouse Entorhinal Cortex in Vitro
  • Spared Premotor Areas Undergo Rapid Nonlinear Changes in Functional Organization Following a Focal Ischemic Infarct in Primary Motor Cortex of Squirrel Monkeys
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.